Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1-14. (canceled)

15. (previously presented) A compound corresponding to formula (I) or a pharmaceutically acceptable salt or isomer thereof:



(I)

wherein:

A is CONH, NHCO, NHC(=S)NH, or NHC(=O)NH;

R_1 to R_4 is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a 5 or 6-member heterocyclic ring;

R_5 and R_6 are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, an amine group, and an alkyl group having 1 to 6 carbon atoms, provided that both of R_5 and R_6 are not hydrogen atoms simultaneously;

B is a group selected from



(I-1)



(I-2)



(I-3)



(I-4)



(I-5)



(I-6)

in which R_7 to R_{17} is independently a hydrogen atom, a halogen atom, or a straight or branched alkyl group having 1 to 6 carbon atoms optionally substituted with more than one halogen atom;

C is an alkyl, alkenyl, or alkynyl group having 1 to 5 carbon atoms which may include one or more heteroatoms, wherein each of m, n, p, q, r, and s is an integer of 0 to 3; and

an asteric mark * indicates a chiral carbon atom; and

(------) mark indicates a double bond or single bond chain.

16. (previously presented) A compound according to claim 15, corresponding to formula (II) or a pharmaceutically acceptable salt or isomer thereof:



(II)

wherein,

R_1 to R_4 is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring; and

R_5 and R_6 are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, amine group and alkyl group having 1 to 6 carbon, provided that both of R_5 and R_6 are not hydrogen simultaneously

17. (previously presented) A compound according to claim 16, wherein said compound is at least one selected from the group consisting of:

N- (4-tert-butylbenzyl)-2- [3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (1-51,KMJ-372),

N-(4-tert-butylbenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (1-52,KMJ-470),

N-(4-tert-butylbenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (1-53,SH-173),

N-(4-tert-butylbenzyl)-2-[3-iodo-4-(methylsulfonylamino)phenyl]propionamide (1-54,SH-168),

N-(4-tert-butylbenzyl)-2-[3,5-difluoro-4-(methylsulfonylamino)phenyl]-propionamide (1-55,SH-285),

N-(4-tert-butylbenzyl)-2-[3-cyano-4-(methylsulfonylamino)phenyl]propionamide (1-56,SH-219),

N-(4-tert-butylbenzyl)-2-[3-methoxycarbonyl-4-(methylsulfonylamino)phenyl]-propionamide (1-57, JMJ-806),

N-(4-*tert*-butylbenzyl)-2-[3-carboxyl-4-(methylsulfonylamino)phenyl]-propionamide (1-58, KMJ-788),

N-4(*tert*-butylbenzyl)-2-[3-methoxycarbonyl-4-(methylsulfonylamino)phenyl]-propionamide (1-59,KMJ-838),

N-(4-tert-butylbenzyl)-2-[3-(benzylamino)carbonyl-4-(methylsulfonylamino)-phenyl]propionamide (1-60,KMJ-836),

N-(4-tert-butylbenzyl)-2-[3-piperidino-4-(methylsulfonylamino)phenyl]-propionamide (1-61,YS-65),

N-(4-tert-butylbenzyl)-2-[3-morpholino-4-(methylsulfonylamino)phenyl]-propionamide (1-62,YS-49),

N-(4-tert-butylbenzyl)-2-[3-(N-Boc)piperazino-4-(methylsulfonylamino)phenyl]-propionamide (1-63,YS-76),

N-(4-tert-butylbenzyl)-2-[3-piperazino-4-(methylsulfonylamino)phenyl]-propionamide (1-64,YS-79),

N-(4-tert-butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-propionamide (1-65,CHK-717),

N-(4-tert-butylbenzyl)-2-[2-fluoro-4-(methylsulfonylamino)phenyl]propionamide (1-66,KMJ-708),

N-(4-tert-butylbenzyl)-2-[2-chloro-4-(methylsulfonylamino)phenyl]propionamide (1-67,KMJ-698),

N-(4-tert-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-7,KMJ-750),

N-(4-chloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-8,YS-85),

N-(3,4-dichloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-9,YS-97),

N-(4-tert-butylbenzyl)-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-propionamide (3-5,SU-834),

N-(4-tert-butylbenzyl)-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-propionamide (3-6,SU-824),

N-(4-chlorobenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-1,SH-291),

N-(4-chlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (4-2, SH-290),

N-(4-chlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (4-3, SH-335),

N-(3,4-dichlorobenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-4, SH-94),

N-(3,4-dichlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (4-5, SH-286),

N-(3,4-dichlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (4-6, SH-337),

N-(4-methylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-7, SH-351),

N-(4-isopropylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-8, KMJ-928),

N-(4-methoxybenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-9, SH-353),

N-(4-trifluoromethylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-propionamide (4-10, SH-93),

N-(4-phenylbenzyl)-2-(3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-1 1, KMJ-498),

N-(l-naphthylmethyl)-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-12, SH-92),

N-(1,2,3,4-tetrahydro-1-naphthalenyl)-2-[3-fluoro-4-methylsulfonylamino)phenyl-propionamide (4-13, SH-112),

N-[2-(4-tert-butylphenyl)ethy]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-propionamide (4-14, KMJ-374),

N-[3-(3,4-dimethylphenyl)propyl]-2-[3-fluoro-4-methylsulfonylamino)phenyl]-propionamide (4-15,SU-770),

N-[3-(3,4-dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4-methylsulfonylamino)-phenyl]propionamide (4-16,SU-774),

N-[3-(3,4-dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4-methylsulfonylamino)-phenyl]propionamide (4-17,SU-776),

N-[3-(3,4-dimethylphenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (4-18,KMJ-686),

N-[3-(4-chlorophenyl)propyl]-2-[3-fluoro-4-methylsulfonylamino)phenyl]-propionamide (4-19,KMJ-518),

N-[3-(4-chlorophenyl)-2-prophenyl]-2-[3-fluoro-4-methylsulfonylamino)phenyl]-propionamide (4-20,KMJ-732),

N-benzyloxy-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-21,SH-109),

N-(benzhydryl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-22,SH-130),

N-(2,2-diphenylethyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-23,SH-116),

N-(3,3-diphenylpropyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-24,KMJ-378),

N-(3,3-diphenyl-2-prophenyl)-2-[3-fluoro-4-methylsulfonylamino)phenyl]-propionamide (4-25,KMJ-724),

N-[3,3-di(4-methylphenyl)-2-propenyl]-2-[3-fluoro-4-methylsulfonylamino)-phenyl]propionamide (4-26,KMJ-908),

N-[3,3-di(4-fluorophenyl)-2-prophenyl]-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (4-27,SH-135),

N-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yliden)ethyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-28,SH-199),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-propionamide (5-1,CHK-512),

N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-propionamide (5-2,CHK-514),

2-[3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]propionamide (5-3,SU-542),

2-[3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-4-tert-butylbenzyl)-3-pivaloxypropyl]propionamide (5-4,SU-564),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonyl-amino)phenyl]propionamide (5-5,CHK-479),

N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-methylsulfonylamino) phenyl]propionamide (5-6,CHK-499),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)-phenyl]propionamide (5-7,KNJ-472),

N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)-phenyl]propionamide (5-8, KMJ-690),

N-[(1R)-1-benzyl-2- (pivaloxy) ethyl]- (2S)-2- [3-fluoro-4- (methylsulfonylamino)-phenyl]propionamide (6-1, SU-730)*

N-[(1S)-1-benzyl-2-(pivaloxy)ethyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-2, SU-634),

N-[(1S)-1-benzyl-2-(pivaloxy)ethyl]-(2R)-2-[3-fluoro-4-methylsulfonylamino)-phenyl]propionamide (6-3, SU-636),

N-[(1R)-1-benzyl-2-(pivaloxy)ethyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-4, SU-728),

N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-5, SU-826),

N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-6, SU-830),

N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-7, SU-838),

N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-8, SU-818),

N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-9, MK-271),

N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-10, MK-272),

N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-11, MK-450),

N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-12, MK-452),

N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-13, MK-453),

N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-14, MK-451),

2-[3-fluoro-4-(methylsulfonylamino)phenyl-2-methylpropionic acid (7-4, CHK-624),

2-(4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (8-11),

2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (8-12),

N-[2-(3, 4-dimethylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-1, CHK-520),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]-2-methylpropionamide (9-2, CHK-543),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonyl-amino)phenyl]-2-methylpropionamide (9-3, CHK-493),

N-[3-(3,4-dimethylphenyl)propyl]-2-[4-(methylsulfonylamino)phenyl]-2-methyl-propionamide (9-4, CHK-591),

N-[3-(3,4-dimethylphenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-5, CHK-656),

N-[3-(3,4-dimethylphenyl)propyl]-2-[-3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-6, CHK-600),

N-(4-tert-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-7, CHK- 715),

N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methyl-propionamide (9-8, CHK-655),

N-(4-tert-butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methyl-propionamide (9-9),

1-[3-fluoro-4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (10-5),

1-[4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (11-7, CHK-530),

1-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (11-8),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[4-(methylsulfonylamino)phenyl] cyclopropane carboxamide (12-1, CHK-533),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[3-fluoro-4-(methylsulfonylamino)-phenyl]cyclopropane carboxamide (12-2, CHK-538),

N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[3-methoxy-4-(methylsulfonyl-amino)phenyl]cyclopropane carboxamide (12-3, CHK-541),

N-[3-(3,4-dimethylphenyl)propyl]-1-[4-(methylsulfonylamino)phenyl]-cyclopropane carboxamide (12-4, CHK-590),

N-[3-(3,4-dimethylphenyl)propyl]-1-[3-fluoro-4-(methylsulfonylamino)phenyl]-cyclopropane carboxamide (12-5),

N-[3-(3,4-dimethylphenyl)propyl]-1-[3-methoxy-4-(methylsulfonylamino)phenyl]-cyclopropane carboxamide (12-6, CHK-632),

N-(4-tert-butylbenzyl)-1-[4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-7, CHK-719),

N-(4-tert-butylbenzyl)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-8, CHK-659), and

N-(4-*tert*-butylbenzyl)-1-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-9, CHK-718).

18. (previously presented) A compound according to claim 15, corresponding to formula (III), or a pharmaceutically acceptable salt or an isomer thereof:



(III)

wherein

R_1 to R_4 is independently hydrogen, halogen, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six- member heterocyclic ring, provided that all of R_1 to R_4 are not hydrogen atoms simultaneously; and

R_5 and R_6 are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, amine group and alkyl group having 1 to 6 carbons, provided that both of R_5 and R_6 are not a hydrogen atom simultaneously.

19. (previously presented) A compound according to claim 18, wherein said compound is selected from the group consisting of:

N-(4-tert-butylbenzyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-1, LJO-328),

N-(4-tert-butylbenzyl)-N'-{1-[3-chloro-4-(methylsulfonylamino)phenyl]ethyl}-thiourea (15-2, CHK-992),

N-(4-tert-butylbenzyl)-N'-{1[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-3, CHK-575),

N-(4-tert-butylbenzyl)-N'-{l-[3-(methoxycarbonyl)-4-(methylsulfonylamino)-phenyl]ethyl}thiourea (15-4, YHS-187),

N-(4-tert-butylbenzyl)-N'-{1-[3-carboxy-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-5, YHS-209),

N- (4-tert-butylbenzyl)-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl} thiourea (16-5, SU-388),

N-(4-tert-butylbenzyl)-N'-{(1S)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (16-6, SU-400),

N-(4-tert-butylbenzyl)-N'-{(1R)-1-[3-fluoro-4-(methylsulfonylamino)phenyl] ethyl}thiourea (17-3, CJU-032),

N-(4-tert-butylbenzyl)-N'-{(1S)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-thiourea (17-6,CJU-039),

N-[(2R)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-1, MK-229),

N-[(2S)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(lR)-1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-2, MK-202),

N-[(2R)-2-benzyl-3-(pivaloyloxy)propyl]-N'-1(1S)-1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-3,MK-230),

N-[(2S)-2-benzyl-3-(pivaloyloxy)propyl]-N-{(1S)-1-[4-(methylsulfonylamino)-phenyl]ethyl)thiourea (18-4,MK-228),

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N′{1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-5, LJO-388),

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonyl-amino)phenyl]ethyl}thiourea (l8-6, SU-472),

N-[(2R)-2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(1R)-1[4-(methyl-sulfonylamino)phenyl]ethyl}thiourea (18-7, SU-512),

N-[(2S)-2-(3, 4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonyl-amino)phenyl]ethyl}thiourea (18-8),

N-[2-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-9, LJO-401),

N- [2-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonyl-amino)phenyl]ethyl}thiourea (18-10, MK-296),

N-[2(R)-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonyl-amino)phenyl]ethyl}thiourea (18-11, MK-334),

N-[2(S)-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonyl-amino)phenyl]ethyl}thiourea (18-12, MK-298),

N-[2-(3,4-(dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[3-fluoro-4-(methyl-sulfonylamino)phenyl]ethyl}thiourea (18-13, LJO-344),

N-[2-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[3-fluoro-4-(methylsulfonyl-amino)phenyl]ethyl}thiourea (18-14, LJO-366),

N-[(2R)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(R)-α-methyl-4-(methylsulfonyl-amino)benzyl]thiourea (19-13,SU-692),

N-[(2S)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(R)-α-methyl-4-(methylsulfonyl-amino)benzyl]thiourea (19-14, SU-704),

N-[(2R)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(S)-α-methyl-4-(methylsulfonyl-amino)benzyl]thiourea (19-15, SU-720),

N-[(2S)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(S)-α-methyl-4-(methylsulfonyl-amino)benzyl]thiourea (19-16, SU-710),

N-(4-*tert*-butylbenzyl)-N'-{1-4-(methylsulfonylamino)-3-fluorophenyl] propyl}-thiourea (20-12, LJO-399),

N-(4-*tert*-butylbenzyl)-N'-{-1-[4-(methylsulfonylamino)-3-fluorophenyl]-2-methyl-propyl}thiourea (20-13, LJO-402),

N-(4-*tert*-buty1benzyl)-N'-{[4-(methylsulfonylamino)-3-fluorophenyl](phenyl)-methyl)thiourea (20-14, LJO-403),

N-4-tert-butylbenzyl)-N'-{1-[4-(methylsuffonylamino)-3-fluorophenyl]-2-phenylethyl)thiourea (20-15, LJO-395),

N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[4-(methylsulfonylamino)phenyl]- ethyl}-thiourea (21-7, CHK-593),

N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[3-fluoro-4-(methylsulfonylamino)-phenylethyl}thiourea (21-8, CHK-660),

N-(4-*tert*-butylbenzyl)-N'-{l-methyl-1-[3-methoxy-4-methylsulfonylamino)phenyl]-ethyl}thiourea (21-9, CHK-629),

N-(4-tert-butylbenzyl)-N'-{1-[4-(methylsulfonylamino)phenyl]- cyclopropyl}-thiourea (22-7, CHK-579),

N-(4-*tert*-butylbenzyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]-cyclopropyl}thiourea (22-8), and

N-(4-*tert*-butylbenzyl)-N'-{1-[3-methoxy-4-(methylsulfonylamino)phenyl]-cyclopropyl}thiourea (22-9, CHK-631).

~~21~~ 20. (currently amended) A compound according to claim 15, corresponding to formula (IV), or a pharmaceutically acceptable salt or isomer thereof:



(IV)

wherein,

R_1 to R_4 is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or five or six-member heterocyclic ring; and

R_5 and R_6 are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of a halogen atom, amine group and alkyl group having 1 to 6 carbons, provided that both of R_5 and R_6 are not hydrogen atoms simultaneously.

21. (previously presented) A compound according to claim 20, wherein said compound is

N-(4-*tert*-butylbenzyl)-N'-1-[4-(methylsulfonylamino)phenyl]ethyl}urea (23-1, MK-82), or

N-(4-*tert*-butylbenzyl)-N'-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}- urea (23-2,MK-205).

22. (previously presented) A compound according to claim 15, corresponding to formula (V), or a pharmaceutically acceptable salt or isomer thereof :



(V)

wherein,

R_1 to R_4 is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring; and

R_5 and R_6 are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atoms, amine groups and alkyl groups having 1 to 6 carbons, provided that both of R_5 and R_6 are not hydrogen atoms simultaneously.

23. (previously presented) A compound according to claim 22, wherein said compound is selected from the group consisting of:

N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-acetamide (24-1,KMJ-586),

N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-propanamide (24-2, KMJ-552),
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-2-propanamide (24-3, KMJ-570),
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-propanamide (24-4, CHK-602),
N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-2-propanamide (24-5, CHK-651),
N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl) propanamide (24-6, CHK-534),
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-chlorophenyl)-2-propanamide (24-7, KMJ-558), and
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-butanamide (24-8, CHK-647).

24. (previously presented) A compound according to claim 15, wherein R_1 to R_4 is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring.

25. (previously presented) A compound according to claim 15, wherein R_5 and R_6 are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of a halogen atom, amine group or an alkyl group having 1 to 6 carbons.

26. (previously presented) A pharmaceutical composition comprising a compound according to claim 15 as an active ingredient in an effective vanilloid receptor

antagonizing amount, together with a pharmaceutically acceptable carrier or diluent.

27. (previously presented) A method of treating acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder, irritation of skin, eye or mucous membrane, fervescence, coughing, stomach-duodenal ulcer, or inflammatory bowel disease caused by the vanilloid receptor antagonistic activity, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.

28. (previously presented) Method of treating or inhibiting pain or inflammation, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.

29. (currently amended) The ~~pharmaceutical composition~~ method according to claim 27, wherein the respiratory disorder is asthma ~~or method of treating asthma~~ or chronic obstructive pulmonary disease ~~, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15~~ .